timothy sykes logo
B. Riley Ups TOI Price Target Amidst Positive Earnings Outlook Thumbnail
ADD US ONG Google News

B. Riley Ups TOI Price Target Amidst Positive Earnings Outlook

TIM SYKES•UPDATED MAR. 15, 2026, 11:11 AM ET
Reviewed by Bryce Tuohey Fact-checked by Matt Monaco

The Oncology Institute Inc.’s stocks have been trading up by 8.4 percent driven by advancements in cancer treatment therapies.

Healthcare industry expert:

Analyst sentiment – neutral

Market Position & Fundamentals:
The Oncology Institute (TOI) is grappling with significant financial headwinds, evidenced by key profitability ratios such as a negative EBIT margin of -12.8% and a profit margin of -14.38%. Despite generating a revenue of over $393 million, the company suffers from a high-cost structure, indicated by a gross margin of 155.1%, which overshadows earnings potential. Moreover, the negative return on equity at -3046.76% and a troubling price-to-tangible-book ratio of -8.99 suggest substantial operational inefficiencies and financial distress. The weak financial strength is also troubling, with an absence of clear debt-to-equity metrics, raising concerns about balance sheet stability.

Technical Analysis & Trading Strategy:
TOI’s recent weekly price patterns show a modest upward momentum with a closing price of $2.84 on March 13, following an intra-week high of $2.95 on March 12. A consistent pattern of higher lows underscores a bullish undertone. The surge in close price from $2.73 on March 9 to $2.95 on March 12 indicates potential buying interest, suggesting traders should consider entering long positions around $2.80, setting a stop loss just below $2.61 to manage downside risk. Monitoring volume confirmations will be essential to validate this emerging trend.

Catalysts & Outlook:
TOI recently experienced favorable developments, including an upgraded price target to $8 by B. Riley and a marked improvement with its first profitable quarter. The reaffirmation of robust revenue guidance for 2026 substantiates positive prospects for substantial growth driven by Florida contract enhancements and new payer agreements. Additionally, corporate governance strengthening initiatives with strategic board appointments provide cautious optimism. However, while TOI outperformed benchmarks with a 13% post-earnings surge, caution is warranted due to its historical financial weaknesses. Investors should monitor for resistance near the $6-$8 range while eyeing support at $2.50.

Candlestick Chart

Weekly Update Mar 09 – Mar 13, 2026: On Sunday, March 15, 2026 The Oncology Institute Inc. stock [NASDAQ: TOI] is trending up by 8.4%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Recent financial data reveals an intriguing landscape for TOI. The company’s recent share price movements have drawn attention after it consistently traded upwards. It closed at $2.84 on March 13, up from $2.7 on March 10, signifying growing investor confidence. Intraday trading reports on the same day reflect a noteworthy rally, with prices reaching up to $3.39 before stabilizing.

Analyzing key financial metrics, TOI’s gross margin is notably high at 155.1%, pointing to an efficient revenue structure. Despite its current revenue standing at $393.41M, TOI projects a monumental surge with its 2026 expectations. However, challenges persist, as indicated by negative pretax and profit margins at -11.7% and -10.6%, respectively.

The company’s recent earnings report signals a positive trend with a beat on both EPS and sales metrics. The jump in capitated revenues due to recent Florida contracts has underpinned this growth. TOI’s strategy, including expanding medical services agreements, aligns with its revenue projections, implying potential further stock price increases. Nevertheless, the balance sheet displays a current ratio of 1.7, which offers moderate liquidity for continuing operational needs and strategic investments.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading TOI

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”